Preclinical CRO Services
Speak with a Scientist Today!
Schedule a consult today and let's discuss how AniLocus can advance your product from Bench-to-Market.
Worldwide, nearly 545 million people were diagnosed with lung disease. Nearly 4 million people die each year from a respiratory-related illness making disorders such as Chronic Obstructive Pulmonary Disease (COPD) one of the top five leading causes of death. Drug development for lung diseases is a challenging process because of the complex nature of lung diseases and the utilization of translational disease models.
At AniLocus, we want to help your company address these challenges by offering preclinical solutions for respiratory drug and therapy devices development to treat disorders including:
- Acute Respiratory Distress Syndrome (ARDS)
- Chronic Obstructive Pulmonary Disease (COPD)
- Congenital Lung Disease
- Infectious Lung Disease
- Inflammatory Lung Diseases
- Interstitial Lung Disease
- Lung Cancer
- Mesenchymal Stem Cell Therapy
- Obstructive Sleep Apnea (OSA)
- Pulmonary Fibrosis
- Respiratory Function Assessment
- Tuberculosis (TB)
- Rare Lung Diseases*
- Alpha-1 Antitrypsin Deficiency (Alpha-1)
- Birt-Hogg-Dubé Syndrome (BHD)
- Cystic Fibrosis
- Diffuse Idiopathic Pulmonary
- Neuroendocrine Cell Hyperplasia (DIPNECH)
- Hermansky-Pudlak Syndrome (HPS)
- Lymphangioleiomyomatosis (LAM)
- Pulmonary Alveolar Microlithiasis (PAM)
- Pulmonary Alveolar Proteinosis (PAP)
- Pulmonary Langerhans Cell Histiocytosis (PLCH)
We understand the limitations in preclinical models for respiratory diseases include testing but provide novel, state-of-the-art approaches to overcome these challenges to advance your product from bench to market. Contact us for more information.
*Many rare lung diseases can be assessed for safety and effectiveness as part of a Priority Review in preparation for FDA applications for Orphan Drug Designation.
Multiple animal models are used in regenerative medicine preclinical product development including:
- Gene knockout/knockin/trapped
- Transgenic rodents
- Chemically-Induced Point Mutation rodents
- Stress-induced models
- Drug-Induced models
- Wound/Laceration Models
- Metabolically-induced models (Diet-induced, Metabolic disorder, micronutrient deficient)
- And more…
We conduct translational animal studies (in vivo and in vitro) collecting detailed, comprehensive results with rapid turnaround.
Drug modalities are different types of therapeutic agents. Each drug is a customizable tool designed for therapeutic intervention. The question is…does your product work and is it safe?
At AniLocus, we conduct relevant preclinical studies to assess any drug modality:
- Antibodies (nanobodies, monoclonal)
- Gene therapy (CRISPR, TALEN)
- Viral therapy (adenovirus-AAV, lentivirus)
- Oligo- and polypeptides (e.g., stapled and modified peptides)
- Oligo- and polynucleotides (e.g., siRNAs, mRNAs, aptamers)
- Macrocyclic molecules
- Drug conjugates (e.g., antibody–drug conjugates, drug–drug conjugates, fluorescence-labeled drugs)
- Targeted protein degraders (e.g., proteolysis-targeting chimeras (PROTACs) and molecular glues) that induce a chemical knockdown of proteins
- Cellular therapies (stem cells, allogenic, autologous)
Using animal and human cells and tissue we can perform multiple interrogative assays depending on therapeutic area and sample type:
- DNA: Extraction, PCR, ddPCR, qPCR, sequencing, genotyping
- RNA: Gene expression profiling, RT-PCR, miRNA, Next-generation sequencing (Nanostring, Illumina), spatial transcriptomics, In situ hybridization (ISH), Multiplex ISH
- Protein: Immunoassays (ELISA, EIA, Luminex), proteomics, ligand binding assays, protein expression, immunohistochemistry (IHC), immunocytochemistry (ICC), and immunofluorescence (IF)
- And more!
- White, E. S., Thomas, M., Stowasser, S., & Tetzlaff, K. (2022). Challenges for Clinical Drug Development in Pulmonary Fibrosis. Frontiers in pharmacology, 13, 823085. < https://doi.org/10.3389/fphar.2022.823085 >.
- GBD Chronic Respiratory Disease Collaborators (2020). Prevalence and attributable health burden of chronic respiratory diseases, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet. Respiratory medicine, 8(6), 585–596. < https://doi.org/10.1016/S2213-2600(20)30105-3 >.
- GBD 2016 Occupational Chronic Respiratory Risk Factors Collaborators, & GBD 2016 occupational chronic respiratory risk factors collaborators (2020). Global and regional burden of chronic respiratory disease in 2016 arising from non-infectious airborne occupational exposures: a systematic analysis for the Global Burden of Disease Study 2016. Occupational and environmental medicine, 77(3), 142–150. < https://doi.org/10.1136/oemed-2019-106013 >.
- Viegi, G., Maio, S., Fasola, S., & Baldacci, S. (2020). Global Burden of Chronic Respiratory Diseases. Journal of aerosol medicine and pulmonary drug delivery, 33(4), 171–177. < https://doi.org/10.1089/jamp.2019.1576 >.
- Hedner, J., & Zou, D. (2022). New pharmacologic agents for obstructive sleep apnoea: what do we know and what can we expect?. Current opinion in pulmonary medicine, 28(6), 522–528. < https://doi.org/10.1097/MCP.0000000000000920 >.
Need some advice from our experts?
Send us a message or schedule a consultation today.
Together, we will discuss your research needs and generate a preclinical service proposal for your immediate review.